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Background: Familial Mediterranean fever (FMF) is the most common autoinflammatory disorder in the world. It is
characterized by recurrent febrile inflammatory attacks of serosal and synovial membranes. MEFV gene mutations
are responsible for the disease and its protein product, pyrin or marenostrin, plays an essential role in the regulation
of the inflammatory reactions. Although the disease may carry a potential for cardiovascular disorders because of
sustained inflammation during its course, the spectrum of cardiac involvement in children with FMF has not been
well studied. We aimed at defining the frequency and spectrum of cardiac affection in children with FMF. The
correlation between these affections and MEFV gene mutations was searched for to establish the relationship
between cardiac phenotype and the patient's genotype in FMF.
Methods: The present work is a cohort study including 55 patients with the clinical diagnosis of FMF based on
the Tel-Hashomere criteria, confirmed by genetic analysis showing homozygous or compound heterozygous
mutation of MEFV genes. Fifty age- and sex-matched normal children were included as controls. The entire study
group underwent detailed cardiac examination, 12-lead ECG and echocardiography. All data was statistically
analysed using SPSS version-15.
Results: Patients had an average age of 8.5+/−4.2 years; with an average disease duration of 2.1+/−2.2 years;
28 were males. All controls showed no MEVF gene mutations. The most frequent gene mutation of the studied
cases was E148Q mutation seen in 34% of cases and the most frequent compound mutation was E148Q/V726A
seen in 16.6% of cases. Echocardiographic examination revealed pericardial effusion in nine patients. Twelve
had aortic regurgitation; nine had mitral regurgitation and six had pulmonary regurgitation. The most common
mutation associated with pericardial effusion was E148Q/V726A in 5/9 of cases. Valvular involvement were
significantly more common in FMF patients with gene mutations. Also cardiac involvement was more common
in patients with positive consanguinity. However, these cardiac manifestations showed no correlation to age,
family history of FMF, or response to therapy or laboratory data.
Conclusions: In our cohort of children with FMF, cardiac involvement appears to be common. Pericardial effusions
are significantly related to presence of mutation types E48Q, P 369S, V726A. These associations may warrant
genetic screening of children with FMF to detect cardiac risk.* Correspondence: r_hegazy@hotmail.com
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Familial Mediterranean Fever (FMF) is the most com-
mon autoinflammatory. Disorder in the world [1]. It is a
genetic disorder inherited as an autosomal recessive
disease [2] and is characterized by recurrent febrile
inflammatory attacks of serosal and synovial membranes.
FMF predominantly affects the populations arising from
the Mediterranean basin and seen in nearly every
country [3]. Its phenotype includes recurrent attacks of
peritonitis, pleuritis, pericarditis, synovitis, arthritis, and
fever [4]. The Mediterranean gene (MEFV) mutations
are responsible for the disease. Its protein product, pyrin
or marenostrin, plays an essential role in the regulation
of the inflammatory reactions. The MEFV gene contains
10 exons and most of the mutations have been found on
the last exon. Up to recently, 152 mutations and poly-
morphisms have been reported [5].
Although the disease in adults and children may carry
a potential for cardiovascular disorders because of the
sustained systemic inflammation during its course [6],
the spectrum of cardiac involvement in children with
FMF has not been well studied [4]. Impairment of
diastolic function parameters [3], pericarditis and peri-
cardial effusion [7], atrial mechanical delay, increased
P wave dispersion [8], and impaired coronary micro-
vascular function [2], have all been reported in vari-
ous studies. The present work aimed at defining the
frequency and spectrum of cardiac manifestations in
Egyptian children with FMF. The correlation between
these manifestations and MEFV gene mutations was
searched for to establish the relationship between
cardiac phenotype and the patient’s genotype in child-
hood FMF.
Methods
The present work is a cohort study that included 108 chil-
dren with the clinical diagnosis of Familial Mediterranean
Fever. These patients were followed at the Rheumatology
Clinic of the Cairo University Specialized Pediatric Hos-
pital. IRB approval was obtained and a written informed
consents were taken from all parents.
For the purpose of this study, the diagnosis of Familial
Mediterranean. Fever was based on the Tel-Hashomere
criteria. Patients included fulfilled 2 major or 1 major
and 2 minor criteria [9].
Major criteria
1. Recurrent febrile episodes accompanied by
peritonitis, synovitis or pleuritis.
2. Amyloidosis of AA-type without predisposing
disease.
3. Favorable response to continuous colchicine
treatment.Minor criteria
1. Recurrent febrile episodes.
2. Erysipelas-like erythema.
3. FMF in a first-degree relative.
FMF patients were included if under 16 years regard-
less of sex, duration of FMF, age of onset, duration of
FMF attacks, frequency of attacks, family history of FMF,
or clinical presentation. Fifty age and sex matched normal
children were included as controls.
Data collected
Detailed history
History of FMF including:
a. Patient's age at inclusion and age at onset of FMF.
b. Duration of FMF, duration & frequency of
FMF attacks.
c. History of the presenting features (e.g., typical
attacks of fever, abdominal pain, chest pain, joint
disease, skin affection, muscle pain, scrotal pain,
and history of vomiting).
d. History of renal involvement
(amyloidosis, proteinuria or haematuria).
e. History of a laparotomy.
f. History of colchicine medication and response
to therapy.
g. Family history including: parental consanguinity,
history of FMF and history of siblings with FMF.
Complete clinical examination
The exam included vital signs and anthropometric
measurements for height, and weight. Body mass
index was calculated as weight (Kg)/height (m2). A
detailed physical examination was performed with a
particular emphasis on the cardiac examination.
Laboratory investigations
a. 6 ml of venous blood was collected under aseptic
conditions for CBC, ESR and CRP.
b. Mutation analysis: 3 ml of blood was collected for
mutation analysis.
Genomic DNA was extracted from the whole blood
according to the standard procedures using QlAamp Spin
Columns by QlA amp DNA Blood Kits [Cat.No.51104]
[10]. The MEFV gene contains 10 exons and most of the
mutations have been found on the last exon. As of this
publication submission, 152 mutations and polymor-
phisms have been reported. Five mutations account for
70% of the deleterious alleles: M694V, V726A, M680I,
M694I, E148Q. Four other mutations are less frequent:
Table 1 Demographic data of the clinically diagnosed
FMF
Cases (n = 108) Controls (n = 50) P value
Mean age 8.5 ± 4.2 8.6 ± 3.9 0.78
Range 2–17 3-15
Sex
Male 55(50.9%) 23(46%) 0.47
BMI 21.2 ± 5.1 24.5 ± 6.7 0.69
+ve FH of FMF 21(19.4%) 0 0.02
+ve consanguinity 43.(39.8%) 20(10%) 0.21
Age at onset 6.3 ± 11.3 ys -
Time to diagnosis 1.2 ± 0.4 ys
Duration 2.1 ± 2.2 ys
BMI: body mass index FH: Family history.
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tected were P369S, K695R. These eleven mutations
were searched for. Specimens and DNA extraction:
Genomic DNA was extracted from acid citrate-dex-
trose-anticoagulated whole-blood specimens using the
Genovision GenoM −96 platform according to the manu-
facturer's instructions.
Detection of FMF mutations: A laboratory-developed
test using the ABIPRISM SNaPshot Multiplex kit, re-
gions of exons 2, 3, 5, and 10 of the MEFV gene were
amplified by multiplex polymerase chain reaction (PCR)
and the amplicons were used as templates in single
base-pair extension (SNaPshot) reaction.
Mutations in the 158 samples were assessed by ampli-
fying genomic DNA with use of primers [11]. M694V,
V726A, M680I, M694I, E148Q, A744S, I692del, R761H,
F479L, P369S, K695R mutations were analyzed by amp-
lification refractory mutation system (ARMS).
Mutation detection by ARMS
The ARMS assay comprises two complementary reac-
tions each conducted with the same substrate DNA.
One reaction includes an ARMS primer specific for the
normal DNA sequence and cannot amplify mutant DNA
at a given locus. The second reaction includes a mutant-
specific primer and cannot amplify normal DNA. The
same common primer is used in both reactions.
The lack of polymerase chain reaction (PCR) products
according to the use of a specific mutation primer set in
patients suspected of carrying the mutation of FMF
suggests that the patient in question is not carrying the
mutation being probed [12]. However, an appropriate
internal PCR control should be run to show that the
DNA is amplifiable. Therefore, the complementary reac-
tion with the normal primer set serves as an internal
control for PCR amplification and allows discrimination
of homozygotes from heterozygotes [12].
Mutations were assessed by amplifying the genomic
DNA template with three sets of normal and mutant-
specific ARMS primers designed to selectively amplify
the normal or altered sequence of each of the three
MEFV mutations. Each set of primers consisted of three
oligonuleotides. Each DNA sample was tested for the
twelve mutations. The PCR amplification was performed
in a final volume of 25 uL containing 100 ng of purified
genomic DNA, 0.04 U of Ampli Tag Gold (Perkin Elmer,
Branchburg, New Jersey) and its PCR buffer (contains
15 mmol of MgCL2 per U), 0.2 mmol of deoxynucleo-
side 5'-triphosphate mix per L (Gibco BRL, Gautherburg,
Maryland), and 1 mmol of each primer.
Amplification conditions were kept the same for all the
ARMS tests, and the procedure was carried out as follows:
The reaction was heated to 94°C for 9 minutes for dena-
turation, followed by 35 cycles with denaturation at 94°Cfor 10 seconds, and extension at 72°C for 30 seconds.
Final extension was done for 10 minutes at 72°C.
The amplified products were separated by electrophor-
esis on 2% agarose gel. Ethidium bromide staining of the
agarose gel was used to detect the amplified fragments
[13–15]. Further mutation screening was performed
through bidirectional automated DNA sequencing using
the MEFV sequence analysis kit (Canterbury Health
Laboratories) to identify the compound heterozygote
under complete aseptic conditions after withdrawing
0.5 ml of EDTA blood. The DNA sequence variations
were identified per reference sequence.
Collection of urine samples
Urine samples were collected for urine analysis to detect
the presence of abnormalities especially proteinuria or
hematuria.
Electrocardiogram (ECG)
All routine measurements were taken and any ECG
abnormalities were noted.
Echocardiography
Echocardiographic examination was performed at the echo-
cardiography lab CUSPH of Medicine Cairo University.
Transthoracic two dimensional (2D) guided, (M. mode),
color Doppler echocardiogram, and continuous wave
Doppler CW were performedwith a Hewlett-Packard
5500 ultrasonic machine phased array sector scanner with
the 4 and 8 probes according to age. Linear measurements
of LV cavity were obtained. Left ventricle end diastolic
diameter (LVEDD), left ventricle end systolic diameter
(LVESD), interventricular septum (IVS) and posterior wall
(PW) and calculation of fractional shortening (FS%) as an
indicator of LV systolic function were done according to
the recommendations of the American Society of Echo-
cardiography. FS value < 28% were considered lower than
Table 2 Clinical Manifestations of the study group
Clinical manifestations No Percent






Chest pain 47 43.5%
Skin rash 41 38.0%
Neurological symptoms 11 10.2%
Appendicectomy 3 2.7%
Scrotal involvement 2 3.6%
Renal symptoms 0 0.0%
GITS: gastrointestinal symptoms.
Table 4 The different mutation types of MEFV gene
among the cases
Cases
Mutation type E148Q Count 35
% within group 34.0%
M680I Count 19
% within group 18.4%
M694I Count 14
% within group 13.6%
P369S Count 6
% within group 5.8%
V726A Count 29
% within group 28.2%
Total Count 103
% within group 95.4%
Table 5 Compound mutations among the FMF cases
Cases
Mutation type E148Q/M680I Count 10
% within group 34.0%
E148Q multiple allele Count 7
% within group 6.4%
E148Q/M6941 Count 6
% within group 18.4%
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tricular mass (LVM) was estimated by using the anatomic-
ally validated formula of Devereux et al. [17]. Myocardial
performance index (MPI), early diastolic peak flow vel-
ocity (A) and E/A ratio were calculated [18].
The echocardiographers were blinded as to whether
the examined study participant was a case or a control.
Data were statistically described in terms of range,
mean ± standard deviation (± SD), frequencies (number
of cases) and percentages when appropriate. Comparison
of quantitative variables between the study groups was
done using Student t test for independent samples in
comparing 2 groups when normally distributed and Mann
Whitney U test for independent samples when not
normally distributed. For comparing categorical data, Chi
square (c2) test was performed. Exact test was used
instead when the expected frequency was less than 5. A
probability value (p value) less than 0.05 was considered
statistically significant. All statistical calculations were
done using computer programs Microsoft Excel 2007
(Microsoft Corporation, NY, USA) and SPSS (Statistical
Package for the Social Science; SPSS Inc., Chicago, IL,
USA) version 15 for Microsoft Windows.Table 3 Laboratory Investigations of the Study Group
Mean SD Median Range
ESR mmHg 30.9 31 19 5–150
Creatinine mg/dl 0.53 0.13 0.5 0.1–1
HB g/dl 11.1 1.5 11.3 6.2–14
TLC 8.1 4.4 7.2 3–31
Neut. % 51.1 16.7 50 17–86
ESR: erythrocyte sedimentation rate. TLC: total leucocytic count.Results
The demographic data of the study group is shown in
Table 1. Abdominal pain was the most common clinical
presentation of FMF in our group (n = 106, 98%) followed
by fever in 102 (94.4%) patient. Other manifestations are
shown in Table 2. The laboratory investigations of the
FMF cases showed that 53.7% (n = 58) had positive urinary
casts, 31.5% (n = 34) had oxalates and 20.4% (n = 22) had
proteins in their urinanalysis. Twelve percent (n = 13) had
high CRP levels. Erythrocyte sedimentation rate, creatin-
ine levels and CBC are shown in Table 3. All controls
showed no MEVF gene mutation. Five (4.6%) of the
FMF cases showed normal gene analysis while 103
(95.4%) showed gene mutations. Two female FMFE148Q/V726A Count 18
% within group 13.6%
V726A multiple allele Count 4
% within group 3.7%
M680I/P369S Count 3
% within group 5.8%
M6941/V726A Count 5
% within group 28.2%
Total Count 53
% within group 49%
Table 6 Cardiac manifestations seen in 39/55 cases
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gous. Fifth-three (49%) showed compound heterozygous
mutations. The different gene mutations are shown in
Tables 4 and 5.
The most frequent gene mutation of the studied cases
was E148Q mutation, seen in 34% of cases and the most
frequent compound mutation was E148Q/V726A
(16.6%). Importantly, all patients with simple heterozy-
gous mutations were excluded from the present work.
Seventy-four percent (n = 39) of the FMF patients
showed a good response to therapy. This “good response”
was defined by less than 2 attacks/year while 26% (n = 14)
showed fair response, defined by 4–5 attacks/year. None
of our FMF patients were resistant to treatment.
Cardiac evaluation of FMF patients
Thirty-nine FMF cases (74%) had cardiac complaints;
the most common of which was palpitations in 59%
(Table 6). Many patients showed more than one
complaint. All patients had normal blood pressure.
Echocardiographic testing revealed pericardial effusions
in 9 patients. Seven had mild and 2 had moderate effu-
sions. None had cardiac tamponade. Twelve had aortic
regurgitation: 8 had grade I and 3 had grade II. Nine had
mitral regurgitation: 5 had grade I, 3 had grade II, and 1
had grade III. Six had pulmonary regurgitation; all 6
were grade I. All patients had sinus rhythm with normal
axis. No significant differences were noted on 12 lead
ECG between both the two groups.Table 7 Frequency of valvular lesions among the different Ge
E148Q/M680I E148Q E148Q/M694
Pulmonary (n = 6) no 1 1 2
% 16.6% 16.6% 33.3%
Mitral (n = 9) no 2 3 0
% 22.2% 33.3% 0.0%
Aortic (n = 12) no 4 2 4
% 33.3% 16.6% 33.3%Relation between cardiac involvement and gene
mutations
The most common mutation associated with pericardial
effusion was E148Q/V726A (5/9 cases). The next most
common association was the E148Q multiple allele
mutation (3/9 cases). The M680I/ P369S mutation was
present in 1/9 of cases. Valvular involvement of the heart
was significantly more common in FMF patients with
gene mutations and only one patient with no FMF gene
mutation had mild mitral regurgitation. Cardiac involve-
ment was significantly more common in patients with
compound heterozygous mutations (n = 27) as compared
to those with simple mutations (n = 12, p = 0.003). The
distribution of valvular disease among the different gene
mutations are shown in Table 7. E148Q mutation was
the most commonly identified mutation among FMF
patients with cardiac involvement. Cardiac involvements
were more common in patients with positive consan-
guinity (p = 0.035). However, cardiac disease in these
patients showed no correlation to age, family history of
FMF, response to therapy, or laboratory data.
Discussion
Defining children with FMF has proved more challen-
ging than previously thought. FMF has traditionally been
considered an autosomal recessive disease. However
clinical phenotypes among patients who are hetero-
zygous for FMF has been repeatedly reported and the
genetics of FMF has been found more complex than
previously appreciated, suggesting partial penetrance
and variable expression [19].
Heterozygous FMF patients tend to have mild disease.
Patients with other inflammatory conditions as Behcet’s
disease and tuberculosis [20] have been found to test
positive for MEFV gene mutation. The vast majority of
these Behcet’s and TB patients have single mutations
[21]. For patient selection we have excluded hetero-
zygous FMF patients with single gene mutations and
included only homozygous FMF patients and those with
compound heterozygous mutations.
The present work reports an incidence of pericarditis
of 16.4% and valvular involvement of 49% in thesene mutation type
Mutation type
1 E148Q/V726A V726A M680I/P369S M6941/V726A
0 2 0 0
0.0% 33.3% 0% 0%
1 3 0 0
11.1% 33.3% 0% 0%
1 0 0 1
8.3% 0% 0% 8.3%
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zygous FMF mutations. The valvular disease detected
consisted of aortic (21.8%), mitral (16%), and pulmonary
regurgitation (11%) involvement.
In a study by Maisch et al. [22], 5% of patients with
FMF (adults) were found to present to the emergency
department for non-acute myocardial infarction-type
chest pain mainly accounted for by pericarditis. Recur-
rent pericarditis may occur in 15-30% of FMF patients.
Examination of the pericardial fluid typically reveals
activation of proinflammatory cytokines such as IL-6,
IL-8, and interferon gamma [23]. Reports on the fre-
quency of pericarditis in FMF are quite variable. In a
retrospective study by Kees et al. [24] that included 4000
FMF patients during a 20 year period, the prevalence of
pericarditis was reported to be 0.7%. The Turkish FMF
study group reported the incidence of pericarditis to be
1.4% in a cohort study [25]. Dabestani etal. [26], though,
reported a much higher prevalence (27%) of pericarditis
in patients with FMF. The often asymptomatic course of
pericarditis in most cases of FMF and the various diag-
nostic methods of detecting pericarditis are most likely
responsible for these variations [27].
Certain mutations in the MEVF gene result in uncon-
trolled neutrophil activation and inflammation in several
tissues. However, the present work suggests that the mu-
tations in the E 148Q and V726A are most commonly
associated with pericarditis in contrast to other muta-
tions. This finding suggests that cardiac screening in pa-
tients with FMF gene mutation prone to pericarditis
may be useful. It is important to emphasize for the clin-
ician that FMF should be also considered in children
presenting with non-infectious pericarditis. Cardiac
functions were well preserved in our patients with FMF.
Previous studies have shown that left ventricular dia-
stolic function indices are commonly impaired in FMF
patients [28]. Systolic dysfunction and cardiac failure
commonly follow these alterations in LV diastolic func-
tions [29]. None of these changes were observed in our
patients. This may be due to the younger age of our
study population and hence the shorter duration of dis-
ease and less time for chronic changes, as it appears that
the main pathophysiologic mechanism for these impair-
ments may be the chronic inflammation over time. This
chronic inflammation through a cumulative effect may
accelerate the development of atherogenesis and throm-
bosis [28]. Subclinical amyloidosis might be another fac-
tor in the pathogenesis of diastolic dysfunction in this
disease, again a pathology progressive with time [30].
On the other hand, cardiac function has been investi-
gated in children with FMF by using conventional &
tissue Doppler imaging [3]. Systolic function was
found to be normal, while diastolic dysfunction was
reported. This was not observed in this study. Valvularinvolvement was noted in 27 (49%) of our patients. No
correlation was found between valvular involvement & the
type of genetic mutations. However, none of the children
with FMF showed valvular disease in the absence of
genetic mutations. Further studies including a larger
number of children will be needed to further evaluate
these associations.
Conclusions
Cardiac involvement is common in children with FMF.
Pericardial effusions are significantly related to the pres-
ence of mutation types E 148Q, P 369S, V726A. These
associations suggest the possibility that genetic screening
of FMF patients to detect risk for significant FMF heart
involvement may be prudent.
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